The serotonergic system in motor and non-motor manifestations of Parkinson’s disease

Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson’s Disease

(2014) Susan H. Fox et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Serotonin transporter inhibition attenuatesl-DOPA-induced dyskinesia without compromisingl-DOPA efficacy in hemi-parkinsonian rats

(2012) Christopher Bishop et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model

(2012) Zacharias Kohl et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease

(2012) Philippe Huot et al.   MOVEMENT DISORDERS

Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease

(2012) Katrina L. Paumier et al.   MOVEMENT DISORDERS

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

(2012) I. H. Richard et al.   NEUROLOGY

Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT

(2012) L. Descarries et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias

(2011) Golnasim Riahi et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

(2011) Kristin B. Dupre et al.   EXPERIMENTAL NEUROLOGY

Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia

(2011) Nina Nevalainen et al.   JOURNAL OF NEUROCHEMISTRY

Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time

(2011) P. Huot et al.   JOURNAL OF NEUROSCIENCE

Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease

(2011) Benedicte Ballanger et al.   MOVEMENT DISORDERS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

(2011) Klaus Seppi et al.   MOVEMENT DISORDERS

Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation

(2011) Corinne Y. Ostock et al.   NEUROPHARMACOLOGY

Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation

(2011) Young C. Chung et al.   NEUROPHARMACOLOGY

The serotonergic system in Parkinson's disease

(2011) Philippe Huot et al.   PROGRESS IN NEUROBIOLOGY

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia

(2010) Daniella Rylander et al.   ANNALS OF NEUROLOGY

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

(2010) Benedicte Ballanger et al.   ARCHIVES OF NEUROLOGY

Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction

(2010) N. Pavese et al.   BRAIN

Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats

(2010) Suk J. Gil et al.   BRAIN RESEARCH BULLETIN

The Roles of Striatal Serotonin and l-Amino-acid Decarboxylase on l-DOPA-induced Dyskinesia in a Hemiparkinsonian Rat Model

(2010) Sukju Gil et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Current Use of Clozapine in Parkinson Disease and Related Disorders

(2010) Alissa A. Thomas et al.   CLINICAL NEUROPHARMACOLOGY

Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats

(2010) Yoshihiro Tani et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter

(2010) Karl Strecker et al.   JOURNAL OF NEUROLOGY

Increased 5-HT2Areceptors in the temporal cortex of parkinsonian patients with visual hallucinations

(2010) Philippe Huot et al.   MOVEMENT DISORDERS

Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study

(2010) Marios Politis et al.   NEUROBIOLOGY OF DISEASE

Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease

(2010) Sylvia Navailles et al.   NEUROBIOLOGY OF DISEASE

Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

(2010) M. Politis et al.   NEUROLOGY

Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine

(2010) Katsuaki Suzuki et al.   PLoS One

Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study

(2009) Giuseppe Meco et al.   JOURNAL OF NEURAL TRANSMISSION

l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia

(2009) Hanna S. Lindgren et al.   JOURNAL OF NEUROCHEMISTRY

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats

(2009) Christopher Bishop et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys

(2009) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats

(2009) C. Marin et al.   PSYCHOPHARMACOLOGY

The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats

(2009) Karen L. Eskow et al.   SYNAPSE

Depressive illness in Parkinson’s disease – indication of a more advanced and widespread neurodegenerative process?

(2008) S. E. Pålhagen et al.   ACTA NEUROLOGICA SCANDINAVICA

Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration

(2008) T. Carlsson et al.   BRAIN

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

(2008) A. Munoz et al.   BRAIN

Serotonin Receptors

(2008) David E. Nichols et al.   CHEMICAL REVIEWS

Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson’s Disease Dementia

(2008) Sally I. Sharp et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study

(2008) V. Caretti et al.   JOURNAL OF NEURAL TRANSMISSION

The history of dopamine and levodopa in the treatment of Parkinson's disease

(2008) Stanley Fahn   MOVEMENT DISORDERS

Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB

(2008) Isabelle Boileau et al.   MOVEMENT DISORDERS

Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat

(2008) Kristin B. Dupre et al.   NEUROPHARMACOLOGY

The neuropathological basis for depression in Parkinson's disease

(2008) Pasquale G. Frisina et al.   PARKINSONISM & RELATED DISORDERS

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model

(2008) K VANOVER et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR